Trial Profile
Early phase II study of TAC-401 in H. pylori-positive subjects. -Eradication of H. pylori-
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Jun 2016
Price :
$35
*
At a glance
- Drugs TAC 401 (Primary)
- Indications Helicobacter pylori infections
- Focus Therapeutic Use
- Sponsors Taiho Pharmaceutical
- 06 Jun 2016 New trial record